Patient Education Sheet Library
Search Results
Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine and Dexamethasone
The combination of brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone (BrECADD) is used for…
Treatment Given by Infusion Treatment Taken by MouthDownloads:
Download (English)Ibrutinib and Rituximab
The combination of ibrutinib and rituximab is used for chronic lymphocytic leukemia (CLL), small lymphocytic…
Treatment Given by Infusion Treatment Given by Injection Treatment Taken by MouthDownloads:
Acalabrutinib and BR
The combination of acalabrutinib, bendamustine, and rituximab is used for mantle cell lymphoma (MCL).
Treatment Given by Infusion Treatment Given by Injection Treatment Taken by MouthDownloads:
Lenalidomide and Rituximab
The combination of lenalidomide and rituximab (R2) is used for follicular lymphoma or marginal zone…
Treatment Given by Infusion Treatment Given by Injection Treatment Taken by MouthDownloads:
Deferasirox
Deferasirox is used for people with an increased amount of iron in their blood for…
Treatment Taken by MouthDownloads:
Decitabine and Venetoclax
The combination of decitabine and venetoclax is used for acute myeloid leukemia (AML).
Treatment Given by Infusion Treatment Taken by MouthDownloads:
Epcoritamab and R2
The combination of epcoritamab and R2 (lenalidomide and rituximab) is used for follicular lymphoma.
Treatment Given by Infusion Treatment Given by Injection Treatment Taken by MouthDownloads:
Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone
The combination of polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) is used for certain…
Treatment Given by Infusion Treatment Taken by MouthDownloads:
Downloads:
Azacitidine and Venetoclax
The combination of azacitidine and venetoclax is used for acute myeloid leukemia (AML).
Treatment Given by Infusion Treatment Given by Injection Treatment Taken by MouthDownloads:
Popular Searches
PES Review Committee
The Patient Education Sheet (PES) Committee is a multidisciplinary team of oncology professionals who guide the development and review of these important resources. This committee ensures that every PES is accurate, clear, and meaningful for patients and caregivers navigating cancer treatment.
Led by NCODA and supported through collaboration with three leading professional organizations—ACCC, HOPA, and ONS—the committee combines expertise from across the oncology care spectrum. Together, they uphold best practices, promote consistency in patient education, and remain committed to improving outcomes through accessible, patient-centered information.
